Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

EP: 1.Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP: 2.Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

EP: 3.Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

EP: 4.RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

EP: 5.Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

EP: 6.Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

Now Viewing

EP: 7.Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

EP: 8.Emerging Therapies in RCC: Shaping Future Treatment Sequences

EP: 9.RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

Video content above is prompted by the following:

• Could you highlight key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib in inoperable aRCC after ICI treatment and other relevant studies?
• What insights do real-world data and experience provide about sequencing strategies and the efficacy of TKIs after prior ICI therapy?
• Real-world outcomes with cabozantinib after prior ICI
• Are there any patients in which you consider immunotherapy rechallenge after progression on initial ICI-based therapy? How might you differentiate between rechallenging with PD-L1 inhibitors vs CTLA-4-based approaches?
• What insights do emerging data, such as the TiNivo-3 trial, provide regarding this strategy? Phase 3 TiNivo-2 trial investigating tivozanib ± nivolumab after an ICI